| Abstract: | In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below:
wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy;
wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and
wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
|
|
Patent landscape, scope, and claims: |
United States Patent 8,859,551 Scope, Claim Construction, and US Patent Landscape for Topical Brimonidine in Inflammatory Dermatologic Disorders
United States Patent 8,859,551 protects a simple US method-of-use construct: topically administering brimonidine (or a pharmaceutically acceptable salt, including brimonidine tartrate) to reduce the severity of one or more symptoms of an inflammatory dermatologic disorder related to the skin. The claims are broad on the therapeutic indication class and narrow on the active ingredient and route (topical) and on the relief endpoint (“reduce the severity of one or more symptoms”). The patent’s practical value is driven by how “inflammatory dermatologic disorder related to the skin” is interpreted, which disorder-specific publications and earlier patents can supply anticipation or obviousness, and which later patents (formulations, additional salts, delivery systems, dosing regimens, and indication refinements) expand or erode exclusivity around topical brimonidine.
What is US Patent 8,859,551 protecting: a topical brimonidine method-of-use for inflammatory dermatologic symptom reduction?
Core protection (as claimed). Claim 1 recites a method of reducing severity of symptoms of an inflammatory dermatologic disorder related to the skin by topically administering an effective amount of brimonidine (or a pharmaceutically acceptable salt). Claims 2 and 4 limit to brimonidine tartrate.
Claim structure and scope.
- Independent claim 1: active ingredient class limited to brimonidine or pharmaceutically acceptable salt; route limited to topical administration to skin; endpoint is symptom severity reduction; disorder is an “inflammatory dermatologic disorder related to the skin.”
- Dependent claims 2 and 4: specific salt form, brimonidine tartrate.
- Claims 3 and 4: duplicate the independent concept with an additional restatement (the text you provided shows claim 3 essentially mirrors claim 1; claim 4 mirrors claim 2 but depends from claim 3).
What is broad.
- The disorder is not named. “Inflammatory dermatologic disorder related to the skin” is the key breadth lever.
- The symptom scope is not limited to a particular symptom set. “One or more symptoms” is open-ended.
- The salt is not limited in independent claim 1 (brimonidine or any pharmaceutically acceptable salt), though tartrate is separately claimed.
What is narrow.
- Topical route is required.
- Brimonidine is required.
- The method is framed as symptom severity reduction, not prophylaxis, not systemic dosing, not combination therapy (nothing in the text you provided explicitly requires a co-therapeutic agent).
Key claim terms likely to drive scope: “inflammatory dermatologic disorder,” “related to the skin,” and “severity”
Because the claims are short and functional, term construction will determine actual enforceable coverage.
- “Inflammatory dermatologic disorder related to the skin.” This likely includes dermatologic inflammatory conditions where inflammation is a central feature (eg, erythematous inflammatory dermatoses). The ambiguity is whether it must be directly inflammatory in pathogenesis, inflammatory as a clinical marker, or broadly any inflammation observed in a skin disorder.
- “One or more symptoms.” Encompasses any measurable or clinically recognized symptom(s) tied to severity, such as erythema/redness, itching/pruritus, papules/pustules, scaling, burning, or other inflammatory symptom endpoints depending on disorder.
- “Reducing the severity.” Functional endpoint that can be proven by clinical scoring, investigator assessment, patient-reported outcomes, or biomarker/lesion metrics, depending on how the specification supports the claim.
How broadly will courts read the claims: are they limited to brimonidine tartrate or any salt?
Claim 1 covers “brimonidine or a pharmaceutically acceptable salt thereof.” That means an accused method using brimonidine as an active free base (if pharmaceutically acceptable) or other salts could fall within claim 1, depending on whether the alternative salt is “pharmaceutically acceptable” and whether infringement theory ties the administered salt to brimonidine.
Claims 2 and 4 narrow to brimonidine tartrate. Those are additive fallbacks if claim 1 is narrowed by claim construction.
Practical infringement trigger
For method-of-use patents like this, the most common infringement theories are:
- Direct infringement where the accused product label instructs or promotes the claimed use, and clinicians apply that regimen.
- Induced infringement where marketing, labeling, or promotional materials encourage topical brimonidine to reduce symptom severity of an inflammatory dermatologic disorder.
When does US Patent 8,859,551 expire, and how does that map to regulatory exclusivity and generic risk?
No patent term details (filing date, nonprovisional filing, priority date, patent term adjustment, PTA) were provided in the prompt. Without those inputs, a precise expiration calculation cannot be produced here. The same applies to the Orange Book status or any FDA reference drug linkage, which requires application and listing data not included in the prompt.
What other US patents typically surround this kind of topical brimonidine method claim (and how do they expand or narrow the estate)?
Even without the full bibliographic record, the landscape for a method-of-use patent on topical brimonidine in inflammatory dermatologic disorders usually splits into five technical “rings” of IP:
-
Formulation and composition patents
- Concentration ranges of brimonidine base or salts.
- Vehicles, penetration enhancers, emulsions, gels, creams, foams, liposomes, nano-carriers.
- Stabilizers and pH specifications for salt stability and skin tolerability.
-
Device and delivery system patents
- Applicators, pumps, transdermal/topical delivery devices.
- Patch formats, controlled-release matrices, occlusive systems.
-
Dosing regimen patents
- Frequency (once/twice daily), duration of treatment course, titration schedules.
- Treatment initiation rules based on lesion severity and response.
-
Indication and symptom refinement patents
- Disorder-specific claims (eg, rosacea subtype-specific, eczema subtype-specific, psoriasis inflammatory symptom endpoints).
- Claims targeting specific symptom endpoints (erythema score, pruritus score, lesion count, etc.).
-
Combination therapy patents
- Brimonidine plus another anti-inflammatory, anti-itch, steroid-sparing agent, or vascular modulator.
- Fixed-dose combination compositions.
How this matters for freedom-to-operate (FTO)
- A generic or competitor can sometimes avoid a pure method-of-use claim by using brimonidine in a different manner that does not meet the endpoint or disorder framing.
- They can also avoid by formulating outside claimed concentration or delivery system boundaries, if composition/delivery patents exist.
What does the patent likely require for validity: anticipation and obviousness fault lines
The claims you provided are broad and therefore vulnerable if the prior art discloses:
- Topical brimonidine for inflammatory dermatologic disorders with clinical severity endpoints, or
- Use of brimonidine (or a known salt) to reduce dermatologic inflammatory symptoms, or
- A combination of references making it obvious to apply brimonidine topically to treat inflammatory dermatoses and reduce symptom severity.
Typical prior art sources that challenge scope
- Early brimonidine development for ophthalmic uses and downstream repurposing in dermatology.
- Patents on alpha-adrenergic agonists used topically for inflammatory erythematous or vasoreactive dermatoses.
- Journal articles on brimonidine’s anti-erythema or anti-inflammatory effects in skin.
Because the claim is not limited to a named disorder, prior art showing symptom reduction for any qualifying inflammatory dermatologic disorder can be relevant.
What generic entry risks exist for topical brimonidine under this specific claim scope?
A generic applicant faces a method-of-use obstacle if:
- The FDA labeling (or promotional materials, depending on enforcement) instructs or encourages topical brimonidine for an inflammatory dermatologic disorder with the same symptom severity reduction intent.
- The applicant’s proposed clinical indications and instructions match the claim language.
Switching the salt form
Claims 1 covers “pharmaceutically acceptable salts.” Changing salt form does not eliminate risk unless the alternative salt is argued to be outside “pharmaceutically acceptable” (rare) or outside what the accused method uses.
Avoiding “severity reduction”
Trying to reframe the use as prevention without addressing symptom severity reduction may reduce method-of-use risk, but if the clinical outcome is the same symptom improvement, enforcement can still land on substance over form.
Which formulation patents may be harder to design around than the method-of-use claim?
If there are composition patents in the same program family, they can be the dominant barriers:
- Concentration windows (eg, 0.1% to 1% brimonidine equivalents)
- pH and vehicle system requirements that make skin delivery work
- Particle size, viscosity, or penetration enhancer choices
Competitors often find that they can’t simply change the method-of-use claim because formulation patents still block product manufacture and sale.
How does US Patent 8,859,551 compare with typical brimonidine dermatology IP (method-only vs layered IP)?
This patent is method-of-use focused. That typically means it is:
- Easier to read broadly, but
- Harder to enforce absent clear linkage between the accused product’s labeling/use and the claimed outcome.
In contrast, patents on:
- Composition,
- Delivery systems, and
- Dose/vehicle/rheology
tend to have more manufacturing hooks that can be easier to enforce against generic product sales.
What matters for litigation: how would claim scope be asserted and defended?
Plaintiff’s likely theory
- Show that the accused topical brimonidine product is administered to treat a qualifies as an “inflammatory dermatologic disorder related to the skin,” and that the clinical effects reduce one or more symptoms’ severity.
- Use clinical data and labeled instructions as evidence of intent and practical use.
Defendant’s likely defenses
- Narrow construction of “inflammatory dermatologic disorder” to exclude the accused condition.
- Narrow construction of symptom “severity” measurement or endpoint to avoid the claim’s functional language.
- Carve-outs if the accused product uses a different route (not topical to skin) or if use is outside the claimed method.
How would this patent impact an FDA pathway for a topical brimonidine product?
No FDA application numbers, listed patents, or Orange Book entries were provided. In general, for method-of-use patents, the trigger for listed-patent challenges is often:
- An FDA label carve-in/caron-out dispute over whether the proposed use matches the claimed indication.
- Paragraph IV certifications aligned to the listed patents’ claimed indication and exclusivity.
Is the patent estate strong or weak for topical brimonidine in inflammatory dermatoses?
Based on claim text alone:
- Strengths: broad indication class, broad symptom endpoint, and clear active ingredient + topical route requirement.
- Weaknesses: lack of disorder specificity can invite validity attacks from any prior art using topical brimonidine in a qualifying inflammatory skin condition; enforceability depends on proof of use consistent with the method.
Patent landscape map (what to look for around 8,859,551)
The landscape should be built in five buckets:
- US patents that cite or are cited by 8,859,551
- Same family continuation filings.
- Related method claims or refinements (dose, symptom scores, specific dermatoses).
- US patents claiming topical brimonidine formulations
- Brimonidine salts (including tartrate) in vehicles and delivery systems.
- US patents claiming alpha-adrenergic agonists for dermatologic inflammation
- Overlap in therapeutic rationale and symptom endpoints.
- FDA Orange Book listed patents for the linked dermatologic product
- Confirmation of which claims track to the actual label.
- Litigation records
- Court decisions that construe “inflammatory dermatologic disorder,” determine infringement standards for method-of-use, or address “pharmaceutically acceptable salts.”
Key Takeaways
- US 8,859,551 claims a topical brimonidine method to reduce symptom severity in an “inflammatory dermatologic disorder related to the skin,” with tartrate specifically claimed in dependent claims.
- The estate breadth hinges on how “inflammatory dermatologic disorder” and “severity” are construed; the active ingredient and topical route are fixed.
- Generic and competitor risk is highest when product labeling and promoted clinical use match the claimed symptom-severity reduction in a qualifying inflammatory skin disorder.
- Manufacturing/design-around is typically less relevant to this specific claim than labeling and clinical use alignment, but formulation and delivery patents in the same technical family can create stronger barriers.
FAQs
-
Does US 8,859,551 cover topical brimonidine free base or only salts like tartrate?
Claim 1 covers brimonidine and any pharmaceutically acceptable salt; claims 2 and 4 specifically recite brimonidine tartrate.
-
What happens if a competitor treats a dermatologic condition with topical brimonidine but measures a different clinical endpoint than “severity”?
Infringement turns on whether the method reduces “severity” of one or more symptoms; endpoint framing that still reflects severity reduction is typically difficult to avoid.
-
Can changing from brimonidine tartrate to another brimonidine salt avoid infringement?
Not for claim 1 if the alternative is “pharmaceutically acceptable,” since claim 1 is not limited to tartrate.
-
Is the patent limited to any specific inflammatory dermatologic disorder (eg, rosacea or eczema)?
The claims you provided do not name specific disorders; they use a functional disorder class of “inflammatory dermatologic disorder related to the skin.”
-
How do formulation patents change the risk profile relative to a method-of-use claim like 8,859,551?
Composition and delivery patents can block manufacturing and sales regardless of labeling, whereas a method-of-use claim often depends more directly on the accused use instructions and actual clinical application.
References
- United States Patent 8,859,551 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
